-89%

est. 2Y upside i

HealthcareAI & MLSeed

Convoke unifies your internal knowledge, workflows, and external data into a continuously updating workspace. Automate analysis, codify decision logic, and accelerate outputs across drug development and commercialization.

Rank

#1827

Sector

Biotechnology, AI/ML Software

Est. Liquidity

~5Y

Data Quality

Data: Low

Convoke presents a moderate upside opportunity for a job seeker, driven by a strong team and a large, growing market for AI in biopharma.

Last updated: February 16, 2026

Bull (20%)+300%

Convoke achieves significant market penetration, secures a large Series A/B round at a high valuation, and demonstrates strong customer retention and product expansion.

Base (35%)+75%

Convoke successfully raises its next funding round at a healthy valuation, continues to grow its customer base, and solidifies its product offering.

Bear (45%)-70%

Convoke struggles to differentiate in a crowded market, faces intense competition from incumbents, or fails to secure sufficient follow-on funding, leading to a low-value acquisition or shutdown.

Est. time to liquidity~5.0 years

Community

Valuation Sentiment

Our model estimates -89% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.